Blood cancer study testing CD305 and CD85d markers
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with a B-cell blood cancer, such as B-cell acute lymphoblastic leukemia or a certain kind of lymphoma or chronic blood cancer.
- You cannot have received any prior treatment (like chemotherapy or drugs that affect your immune system) for your cancer.
- You must be willing to sign a consent form agreeing to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines specific markers (PD-L1 and CD276) on blood cancer cells in newly diagnosed patients with B-cell leukemias or lymphomas. Understanding these markers may help doctors better understand your cancer and develop better treatments.
This study looks at inflammatory markers in the blood of people newly diagnosed with B-cell neoplasms (a group of blood cancers and related disorders). It aims to better understand how these markers relate to the disease and may help guide future care.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study looks at whether certain blood cell tests (reticulocyte parameters) can early detect how well your bone marrow is making red blood cells in people newly diagnosed with chronic B-cell cancers. It aims to improve monitoring before standard treatments begin.
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.